• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

A multivariate analysis of the survival of patients with aggressive lymphoma: variations in the predictive value of prognostic factors during the course of the disease. Groupe d'Etudes des Lymphomes de l'Adulte.

作者信息

Mounier N, Morel P, Haioun C, Coiffier B, Tilly H, Chatelain C, Lederlin P, Thyss A, Herbrecht R, Gisselbrecht C, Lepage E

机构信息

Unité d'Information Médicale, CHU Henri Mondor, AP HP, Creteil, France.

出版信息

Cancer. 1998 May 15;82(10):1952-62.

PMID:9587130
Abstract

BACKGROUND

Aggressive non-Hodgkin's lymphoma is now often curable with chemotherapy. The International Prognostic Index (IPI) was recently developed to predict patient survival on the basis of pretreatment clinical features. However, classical multivariate regression models such as the IPI fail to detect time-dependent changes in the predictive value of covariates. In this study, an extension of the Cox proportional hazards model was used to determine whether the value of prognostic factors might decay over time.

METHODS

A total of 1271 patients younger than 60 years, entered on the LNH-84 and LNH-87 studies of an ACVBP induction regimen (consisting of doxorubicin, cyclophosphamide, vindesine, bleomycin, methylprednisolone, and IT methotrexate), were analyzed in terms of overall survival and monthly risk of dying. By a standard method, prognostic factors were identified in a training sample and confirmed in a validation sample. The independently significant covariates were then included in a step-function regression model (3-step) that permitted determination of their value in predicting the short term and long term survival of the entire population.

RESULTS

During the entire follow-up period (median, 5.5 years), lactate dehydrogenase level, tumor stage, performance status, and number of extranodal sites remained independently predictive of overall survival. However, these covariates had nonproportional hazard functions. The study of their time-dependent effect with the 3-step model confirmed that they were predictive of overall survival during the short term follow-up period of 3 months to 2 years. However, during the induction period of 0-3 months and the long term follow-up period of 2-10 years, there was only 1 independently predictive factor for each of these periods: performance status and tumor stage, respectively.

CONCLUSIONS

The IPI factors are relevant to short term follow-up and permit the selection of routine or experimental therapeutic regimens. In contrast, only performance status is predictive of a patient's ability to tolerate induction chemotherapy, and only tumor stage is predictive of long term survival.

摘要

相似文献

1
A multivariate analysis of the survival of patients with aggressive lymphoma: variations in the predictive value of prognostic factors during the course of the disease. Groupe d'Etudes des Lymphomes de l'Adulte.
Cancer. 1998 May 15;82(10):1952-62.
2
Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte.完全缓解后接受一线自体移植治疗的侵袭性非霍奇金淋巴瘤患者的预后因素:成人淋巴瘤研究组的一项队列研究
J Clin Oncol. 2004 Jul 15;22(14):2826-34. doi: 10.1200/JCO.2004.12.032.
3
Prognosis of patients with advanced Hodgkin's disease: evaluation of four prognostic models using 344 patients included in the Group d'Etudes des Lymphomes de l'Adulte Study.
Cancer. 1997 Sep 15;80(6):1124-33.
4
Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.复发侵袭性淋巴瘤的治疗:含与不含高剂量治疗及干细胞救援的方案
Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. doi: 10.1007/s00280-002-0447-1. Epub 2002 Apr 12.
5
Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors.放疗前采用CHOD/BVAM或BVAM化疗方案治疗的中枢神经系统原发性非霍奇金淋巴瘤:长期生存及预后因素
Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):501-8. doi: 10.1016/j.ijrobp.2003.11.001.
6
Cost determinants in aggressive non-Hodgkin's lymphoma.侵袭性非霍奇金淋巴瘤的成本决定因素
Haematologica. 2005 May;90(5):661-71.
7
Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.两种不同的源自ProMACE-CytaBOM方案在晚期侵袭性非霍奇金淋巴瘤中的疗效。GISL进行的一项多中心试验的最终报告。
Haematologica. 1998 Sep;83(9):800-11.
8
Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs.侵袭性恶性淋巴瘤的预后因素:一种可识别需要更强化治疗患者的预后指数的描述与验证。侵袭性淋巴瘤研究组。
J Clin Oncol. 1991 Feb;9(2):211-9. doi: 10.1200/JCO.1991.9.2.211.
9
Treatment results of tonsillar lymphoma: a 10-year experience.扁桃体淋巴瘤的治疗结果:十年经验
Ann Hematol. 2005 Apr;84(4):223-6. doi: 10.1007/s00277-004-0860-0. Epub 2004 Mar 23.
10
Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.卡莫司汀、多柔比星、依托泊苷、长春新碱和环磷酰胺联合米托蒽醌、阿糖胞苷及甲氨蝶呤加亚叶酸钙治疗侵袭性非霍奇金淋巴瘤的长期随访研究
Cancer. 2005 Mar 1;103(5):970-7. doi: 10.1002/cncr.20891.